<VariationArchive VariationID="1077062" VariationName="NM_000091.5(COL4A3):c.600_603dup (p.Phe202fs)" VariationType="Duplication" Accession="VCV001077062" Version="1" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-06-23" DateCreated="2021-05-14" MostRecentSubmission="2021-05-14">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1065661" VariationID="1077062">
      <GeneList>
        <Gene Symbol="COL4A3" FullName="collagen type IV alpha 3 chain" GeneID="1285" HGNC_ID="HGNC:2204" Source="submitted" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>2q36.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="2" Accession="NC_000002.12" start="227164624" stop="227314792" display_start="227164624" display_stop="227314792" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="2" Accession="NC_000002.11" start="228029280" stop="228179507" display_start="228029280" display_stop="228179507" Strand="+" />
          </Location>
          <OMIM>120070</OMIM>
        </Gene>
        <Gene Symbol="MFF-DT" FullName="MFF divergent transcript" GeneID="654841" HGNC_ID="HGNC:41067" Source="calculated" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>2q36.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="2" Accession="NC_000002.12" start="227221052" stop="227325164" display_start="227221052" display_stop="227325164" Strand="-" />
          </Location>
        </Gene>
      </GeneList>
      <Name>NM_000091.5(COL4A3):c.600_603dup (p.Phe202fs)</Name>
      <CanonicalSPDI>NC_000002.12:227251192:GGGA:GGGAGGGA</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>2q36.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="2" Accession="NC_000002.12" start="227251192" stop="227251193" display_start="227251192" display_stop="227251193" variantLength="4" positionVCF="227251192" referenceAlleleVCF="C" alternateAlleleVCF="CGGGA" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="2" Accession="NC_000002.11" start="228115908" stop="228115909" display_start="228115908" display_stop="228115909" variantLength="4" positionVCF="228115908" referenceAlleleVCF="C" alternateAlleleVCF="CGGGA" />
      </Location>
      <ProteinChange>F202fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000002.11" sequenceAccession="NC_000002" sequenceVersion="11" change="g.228115909_228115912dup" Assembly="GRCh37">
            <Expression>NC_000002.11:g.228115909_228115912dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000002.12" sequenceAccession="NC_000002" sequenceVersion="12" change="g.227251193_227251196dup" Assembly="GRCh38">
            <Expression>NC_000002.12:g.227251193_227251196dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_011591.1" sequenceAccession="NG_011591" sequenceVersion="1" change="g.91629_91632dup">
            <Expression>NG_011591.1:g.91629_91632dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000091.5" sequenceAccession="NM_000091" sequenceVersion="5" change="c.600_603dup" MANESelect="true">
            <Expression>NM_000091.5:c.600_603dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000082.2" sequenceAccession="NP_000082" sequenceVersion="2" change="p.Phe202fs">
            <Expression>NP_000082.2:p.Phe202fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_230" sequenceAccession="LRG_230">
            <Expression>LRG_230:g.91629_91632dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_230t1" sequenceAccession="LRG_230t1">
            <Expression>LRG_230t1:c.600_603dup</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="2125924714" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000091.5(COL4A3):c.600_603dup (p.Phe202fs) AND Autosomal dominant Alport syndrome" Accession="RCV001391174" Version="2">
        <ClassifiedConditionList TraitSetID="5740">
          <ClassifiedCondition DB="MedGen" ID="C5882663">Autosomal dominant Alport syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2021-05-14" MostRecentSubmission="2021-05-14">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <ConditionList>
          <TraitSet ID="5740" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="158" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Alport syndrome 3, autosomal dominant</ElementValue>
                <XRef ID="Alport+Syndrome+Dominant+Type/336" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Alport syndrome dominant type</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Renal failure and sensorineural hearing loss</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Autosomal dominant Alport syndrome</ElementValue>
                <XRef ID="MONDO:0007086" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">ALPORT SYNDROME 3A, AUTOSOMAL DOMINANT</ElementValue>
                <XRef Type="MIM" ID="104200" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">ATS3A</ElementValue>
                <XRef Type="MIM" ID="104200" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="624" />
                <XRef ID="624" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">In Alport syndrome (AS) a spectrum of phenotypes ranging from progressive renal disease with extrarenal abnormalities to isolated hematuria with a non-progressive or very slowly progressive course is observed. Approximately two thirds of AS is X-linked (XLAS); approximately 15% is autosomal recessive (ARAS), and approximately 20% is autosomal dominant (ADAS). In the absence of treatment, renal disease progresses from microscopic hematuria (microhematuria) to proteinuria, progressive renal insufficiency, and end-stage renal disease (ESRD) in all males with XLAS, and in all males and females with ARAS. Progressive sensorineural hearing loss (SNHL) is usually present by late childhood or early adolescence. Ocular findings include anterior lenticonus (which is virtually pathognomonic), maculopathy (whitish or yellowish flecks or granulations in the perimacular region), corneal endothelial vesicles (posterior polymorphous dystrophy), and recurrent corneal erosion. In individuals with ADAS, ESRD is frequently delayed until later adulthood, SNHL is relatively late in onset, and ocular involvement is rare.</Attribute>
                <XRef ID="NBK1207" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301386</ID>
                <ID Source="BookShelf">NBK1207</ID>
              </Citation>
              <Citation Type="Translational/Evidence-based" Abbrev="EuroGentest, 2011">
                <ID Source="PubMed">22166944</ID>
              </Citation>
              <XRef ID="63" DB="Orphanet" />
              <XRef ID="88918" DB="Orphanet" />
              <XRef ID="C5882663" DB="MedGen" />
              <XRef ID="MONDO:0007086" DB="MONDO" />
              <XRef Type="MIM" ID="104200" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="3133202" SubmissionDate="2021-05-09" DateLastUpdated="2021-05-14" DateCreated="2021-05-14">
        <ClinVarSubmissionID localKey="NM_000091.4:c.600_603dup|OMIM:104200" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001593073" DateUpdated="2021-05-14" DateCreated="2021-05-14" Type="SCV" Version="1" SubmitterName="Precision Medicine Center, Zhengzhou University" OrgID="507840" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>PVS1:Null variant in the gene with established LOF as a disease mechanism PM2:not found in gnomAD PP3:Multiple lines of computational evidence support a deleterious effect on the gene or gene product</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>research</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="COL4A3" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000091.4:c.600_603dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="104200" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB9604514</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="3133202" TraitType="Disease" MappingType="XRef" MappingValue="104200" MappingRef="OMIM">
        <MedGen CUI="C5882663" Name="Autosomal dominant Alport syndrome" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

